Does TECLISTAMAB Cause Therapy non-responder? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Therapy non-responder have been filed in association with TECLISTAMAB (TECVAYLI). This represents 0.5% of all adverse event reports for TECLISTAMAB.
6
Reports of Therapy non-responder with TECLISTAMAB
0.5%
of all TECLISTAMAB reports
4
Deaths
1
Hospitalizations
How Dangerous Is Therapy non-responder From TECLISTAMAB?
Of the 6 reports, 4 (66.7%) resulted in death, 1 (16.7%) required hospitalization, and 1 (16.7%) were considered life-threatening.
Is Therapy non-responder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TECLISTAMAB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does TECLISTAMAB Cause?
Cytokine release syndrome (257)
Pneumonia (101)
Plasma cell myeloma (100)
Immune effector cell-associated neurotoxicity syndrome (99)
Pyrexia (86)
Covid-19 (82)
Infection (58)
Drug ineffective (52)
Neutropenia (48)
Sepsis (48)
What Other Drugs Cause Therapy non-responder?
ETANERCEPT (3,472)
APREMILAST (3,360)
METHOTREXATE (2,965)
RITUXIMAB (2,731)
ADALIMUMAB (2,595)
PREDNISONE (2,563)
TREPROSTINIL (2,289)
INFLIXIMAB (2,122)
TOCILIZUMAB (1,775)
HYDROXYCHLOROQUINE (1,699)
Which TECLISTAMAB Alternatives Have Lower Therapy non-responder Risk?
TECLISTAMAB vs TECLISTAMAB-CQYV
TECLISTAMAB vs TEDIZOLID
TECLISTAMAB vs TEDUGLUTIDE
TECLISTAMAB vs TEDUGLUTIDE\WATER
TECLISTAMAB vs TEGAFUR